Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0140-6736(22)02115-8 | DOI Listing |
Implement Sci Commun
January 2025
Department of Obstetrics and Gynecology, University of Michigan, 2800 Plymouth Rd., Building #10, Rm G016, Ann Arbor, MI, 48109-5276, USA.
Background: Pain management after childbirth is widely variable, increasing risk of untreated pain, opioid harms, and inequitable experiences of care. The Creating Optimal Pain Management FOR Tailoring Care (COMFORT) clinical practice guideline (CPG) seeks to promote evidence-based, equitable acute peripartum pain management in the United States. We aimed to identify contextual conditions (i.
View Article and Find Full Text PDFNat Commun
January 2025
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Previous work has demonstrated that next-generation sequencing data can be used to identify samples with MSI-high phenotype. However, low tumor purity, as frequently observed in routine clinical samples, poses a challenge to the sensitivity of existing algorithms.
View Article and Find Full Text PDFJAMA Health Forum
December 2024
Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.
Importance: More than one-quarter of US residents live in states or localities that restrict sales of flavored electronic nicotine delivery systems (ENDS), often as a means to reduce youth vaping. Yet, how these policies affect young adult vaping and smoking remains unclear.
Objective: To estimate the effects of ENDS flavor restrictions on ENDS use and cigarette smoking among young adults (age 18-29 years) in the US.
J Med Toxicol
December 2024
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Am J Geriatr Psychiatry
November 2024
Department of Bioethics (CRM, SH, SYK), Clinical Center, National Institutes of Health Clinical Center, Bethesda, MD. Electronic address:
Objective: The new antiamyloid medications Lecanemab (Leqembi) and donanemab (Kisunla) are the first disease-modifying treatments for Alzheimer's disease (AD) to receive full FDA approval. However, some commentators question whether the drugs' benefits outweigh their risks, burdens, and costs to patients. This study assessed the perceived value of these medications by asking caregivers of persons with AD to compare them to a widely used intervention in AD management: home-based care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!